With the help of this model and pharmacological analysis we have designed the study to find out the outcome of the interaction between DNMT inhibitors, decitabine or zebularine, and classic anticancer chemotherapeutics used in the treatment of CRC such as oxaliplatin, an inter- and intra-DNA cross-linking agent, and 5-fluorouracil, a thymidylate synthase inhibitor. This evidence concerns the gene DNMT1 and colorectal carcinoma.